{"id":"romiplostim-n01","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Cough"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to the thrombopoietin receptor on megakaryocyte cells, leading to increased platelet production and count. This is particularly useful in treating conditions characterized by low platelet counts, such as immune thrombocytopenia.","oneSentence":"Romiplostim N01 is a thrombopoietin receptor agonist that stimulates platelet production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:39.205Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Immune thrombocytopenia"}]},"trialDetails":[{"nctId":"NCT07400250","phase":"PHASE2","title":"Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-04-01","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":28},{"nctId":"NCT07321626","phase":"PHASE1","title":"Romiplostim N01 for Platelet Recovery After Haploidentical HSCT","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-06-01","conditions":"Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome), Delayed Platelet Engraftment","enrollment":130},{"nctId":"NCT07345000","phase":"PHASE3","title":"A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-01","conditions":"Treatment-naïve Severe Aplastic Anemia","enrollment":210},{"nctId":"NCT07206823","phase":"NA","title":"Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-09-01","conditions":"Primacy Immune Thrombocytopenia","enrollment":30},{"nctId":"NCT07185893","phase":"NA","title":"A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Jun wang","startDate":"2025-09","conditions":"Solid Tumor Malignancies, Cancer, CTIT-Chemotherapy Induced Thrombocytopenia, Thrombocytopenia","enrollment":106},{"nctId":"NCT07162519","phase":"NA","title":"Romiplostim N01 in the Treatment of Thrombocytopenia Caused by Cytotoxic Drugs in Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-09-20","conditions":"Cytotoxic Drugs, Romiplostim N01, Breast Cancer","enrollment":68},{"nctId":"NCT07128576","phase":"PHASE2","title":"Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2025-09-15","conditions":"Solid Tumors","enrollment":60},{"nctId":"NCT07063225","phase":"PHASE2","title":"Romiplostim N01 for Chemotherapy-induced Thrombocytopenia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-08","conditions":"Chemotherapy-induced Thrombocytopenia, Romiplostim N01","enrollment":50},{"nctId":"NCT07043894","phase":"PHASE2","title":"Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-07-01","conditions":"Solid Tumors, Hematological Tumor, Children","enrollment":50},{"nctId":"NCT06992128","phase":"PHASE2","title":"Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-05-22","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":129},{"nctId":"NCT06898983","phase":"PHASE2","title":"Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2025-03-31","conditions":"Cancer Treatment-induced Thrombocytopenia (CTIT)","enrollment":97},{"nctId":"NCT06686927","phase":"PHASE2","title":"Study on Glucocorticoid Combined With Gamma Globulin and Ropristine N01 in Treatment of Initial Severe ITP","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-11-20","conditions":"Primary Immune Thrombocytopenia","enrollment":36},{"nctId":"NCT06759636","phase":"PHASE3","title":"FRIENDS-01：A Multicenter Open-label Randomized Controlled Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-01-21","conditions":"CTIT: Cancer Therapy Induced Thrombocytopenia","enrollment":88},{"nctId":"NCT06613880","phase":"PHASE2","title":"Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-10-24","conditions":"Aplastic Anemia, TPO Receptor Agonists","enrollment":48},{"nctId":"NCT06693791","phase":"PHASE2","title":"Romiplostim N01 for Platelet Recovery in Adult Hematologic Malignancies Patients Undergoing UCBT","status":"RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2024-12-01","conditions":"Platelet Recovery After Umbilical Cord Blood Transplantation","enrollment":34},{"nctId":"NCT06658834","phase":"PHASE2","title":"A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-06-01","conditions":"Primary Immune Thrombocytopenia","enrollment":129},{"nctId":"NCT06440824","phase":"PHASE3","title":"A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin","status":"NOT_YET_RECRUITING","sponsor":"Shandong University","startDate":"2024-06-01","conditions":"CTIT-Chemotherapy Induced Thrombocytopenia","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Romiplostim N01","genericName":"Romiplostim N01","companyName":"Qilu Pharmaceutical Co., Ltd.","companyId":"qilu-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Romiplostim N01 is a thrombopoietin receptor agonist that stimulates platelet production. Used for Immune thrombocytopenia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}